The turnover of Basic Pharmaceutical Products and Pharmaceutical Preparations in the UK has demonstrated significant volatility from 2013 to 2023. The peak value of €19.48 billion was achieved in 2018, while the lowest point was €10.71 billion in 2016. The most recent actual data from 2023 shows a slight decrease to €18.28 billion, reflecting a minor 0.03% drop year-on-year. Over the past five years, the compound annual growth rate (CAGR) has been -1.26%. Looking ahead to the forecasted period from 2024 to 2028, turnover is expected to gradually decline with a forecasted CAGR of -0.02%.
Future trends to watch for:
- Potential impacts of regulatory changes and market access, especially with Brexit-related adjustments.
- Technological advancements and innovations in pharmaceutical manufacturing and product development.
- Shifts in global supply chains and their effects on UK's pharmaceutical industry.
- Health policy changes and their implications for pharmaceutical pricing and demand.
Latest reports
US Erectile Dysfunction Market Report- Q1 2025
The US Erectile Dysfunction (ED) market in Q1 2025 is navigating a challenging economic landscape marked by inflationary pressures, geopolitical tensions, and a...
South Korea Erectile Dysfunction Market Report- Q4 2024
The South Korean Erectile Dysfunction (ED) market in the fourth quarter of 2024 is characterized by evolving consumer preferences, technological innovations, and economic...
Spain Erectile Dysfunction Market Report- Q4 2024
The fourth quarter of 2024 presents a dynamic period for the Erectile Dysfunction (ED) market in Spain, marked by significant developments and emerging...
